News Image

BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update

Provided By GlobeNewswire

Last update: Nov 4, 2024

— Q3 2024 ORLADEYO net revenue of $116.3 million (+35.7 percent y-o-y) —

— Full-year 2024 ORLADEYO revenue guidance adjusted to $430-$435 million (top end of prior guidance range) —

Read more at globenewswire.com

BIOCRYST PHARMACEUTICALS INC

NASDAQ:BCRX (2/21/2025, 8:02:57 PM)

After market: 9.25 +0.04 (+0.43%)

9.21

-0.18 (-1.92%)



Find more stocks in the Stock Screener

Follow ChartMill for more